Ganglioneuroblastoma, Nodular

Oncology·MeSH: Neuroblastoma

Prevalence

0.1 / 100K

19 drugs in development·4 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(16)

Drug	Company
Dinutuximab	Black Diamond Therapeutics, Inc. (BDTX)
Dinutuximab	PTC THERAPEUTICS, INC. (PTCT)
Dinutuximab	ENANTA PHARMACEUTICALS INC (ENTA)
etoposide	Black Diamond Therapeutics, Inc. (BDTX)
Etoposide	PTC THERAPEUTICS, INC. (PTCT)
Etoposide phosphate	Black Diamond Therapeutics, Inc. (BDTX)
Isotretinoin	ENANTA PHARMACEUTICALS INC (ENTA)
Isotretinoin	Black Diamond Therapeutics, Inc. (BDTX)
Isotretinoin	PTC THERAPEUTICS, INC. (PTCT)
Isotretinoin	Filana Therapeutics Inc. (FLNA)
Melphalan	PTC THERAPEUTICS, INC. (PTCT)
Melphalan	Black Diamond Therapeutics, Inc. (BDTX)
Thiotepa	PTC THERAPEUTICS, INC. (PTCT)
Thiotepa	Black Diamond Therapeutics, Inc. (BDTX)
Topotecan	Black Diamond Therapeutics, Inc. (BDTX)
Vincristine	Black Diamond Therapeutics, Inc. (BDTX)

Phase 2(2)

Drug	Company
Topotecan	ENANTA PHARMACEUTICALS INC (ENTA)
Topotecan	PTC THERAPEUTICS, INC. (PTCT)

Phase 1(1)

Drug	Company
Thiotepa	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 19 drugs in development for Ganglioneuroblastoma, Nodular across 4 companies.

There are 1 clinical trial targeting Ganglioneuroblastoma, Nodular tracked by BioSniper.

The estimated prevalence of Ganglioneuroblastoma, Nodular is approximately 0.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.